Economic Atlas
Companies/Xenon Pharmaceuticals Inc.
Company profile

Xenon Pharmaceuticals Inc.

NASDAQ: XENE · Healthcare · Biotechnology
Canadian filerHQ Burnaby, BCCIK 0001582313Reports USD
#665 of 1,418 Healthcare companies by revenue
EA Score
56C
Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$345.9M
Employees
364
as of 2026-08-07
Market cap
$6.2B
as of 2026-08-07

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$7.5M$7.5M2025
Net income-$345.9M-$345.9M2025
Operating income-$373.1M-$373.1M2025
Total assets$633.2M$633.2M2025
Liabilities$51.4M$51.4M2025
Equity$581.8M$581.8M2025

Revenue trend

FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY25
FY25
FY25

Revenue by segment

Filed disclosures · FY2022
By product
License and Service100%
By geography

Not disclosed.

The read

What is Xenon Pharmaceuticals Inc.’s revenue?

Xenon Pharmaceuticals Inc. booked $7.5M in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -4612.1% net margin.

Peers · Healthcare
Amazonas Florestal, Ltd——COSCIENS Biopharma Inc.43DCompuMed, Inc.69BOvid Therapeutics Inc.49DNewtopia Inc.——Syra Health Corp. Class A Common Stock51D
Key facts
CEOIan C. Mortimer
SectorHealthcare
IndustryBiotechnology
HeadquartersBurnaby, BC
ExchangeNASDAQ: XENE
Employees364
IPO date2014-11-05
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.